James Wason
Title
Cited by
Cited by
Year
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
S Sawcer, G Hellenthal, M Pirinen, CC Spencer, NA Patsopoulos, ...
23532011
Imaging biomarker roadmap for cancer studies
JPB O'Connor, EO Aboagye, JE Adams, HJWL Aerts, SF Barrington, ...
Nature reviews Clinical oncology 14 (3), 169-186, 2017
5202017
Multi-armed Bandit Models for the Optimal Design of Clinical Trials: Benefits and Challenges
SS Villar, J Bowden, J Wason
Statistical Science 30 (2), 199-215, 2015
1912015
Adaptive designs in clinical trials: why use them, and how to run and report them
P Pallmann, AW Bedding, B Choodari-Oskooei, M Dimairo, L Flight, ...
BMC medicine 16 (1), 1-15, 2018
1752018
Replication analysis identifies TYK2 as a multiple sclerosis susceptibility factor
M Ban, A Goris, ÅR Lorentzen, A Baker, T Mihalova, G Ingram, DR Booth, ...
European journal of human genetics 17 (10), 1309-1313, 2009
1422009
Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?
JMS Wason, L Stecher, AP Mander
Trials 15 (1), 1-7, 2014
942014
Optimal design of multi‐arm multi‐stage trials
J Wason, T Jaki
Statistics in Medicine 31 (30), 4269-4279, 2012
872012
A comparison of Bayesian adaptive randomization and multi‐stage designs for multi‐arm clinical trials
J Wason, L Trippa
Statistics in medicine 33 (13), 2206-2221, 2014
712014
Some recommendations for multi-arm multi-stage trials
J Wason, D Magirr, M Law, T Jaki
Statistical methods in medical research 25 (2), 716-727, 2016
672016
Confounding underlies the apparent month of birth effect in multiple sclerosis
B Fiddes, J Wason, A Kemppinen, M Ban, A Compston, S Sawcer
Annals of neurology 73 (6), 714-720, 2013
622013
What role for genetics in the prediction of multiple sclerosis?
S Sawcer, M Ban, J Wason, F Dudbridge
Annals of neurology 67 (1), 3-10, 2010
572010
Multisystemic therapy versus management as usual in the treatment of adolescent antisocial behaviour (START): a pragmatic, randomised controlled, superiority trial
P Fonagy, S Butler, D Cottrell, S Scott, S Pilling, I Eisler, P Fuggle, ...
The Lancet Psychiatry, 2018
542018
The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
LE Dalton, HJ Clarke, J Knight, MH Lawson, J Wason, DA Lomas, ...
British journal of cancer 108 (6), 1340-1347, 2013
512013
Prospective study evaluating the relative sensitivity of 18F-NaF PET/CT for detecting skeletal metastases from renal cell carcinoma in comparison to multidetector CT and 99mTc …
EL Gerety, EM Lawrence, J Wason, H Yan, S Hilborne, J Buscombe, ...
Annals of Oncology 26 (10), 2113-2118, 2015
462015
Stepped wedge cluster randomized controlled trial designs: a review of reporting quality and design features
MJ Grayling, JMS Wason, AP Mander
Trials 18 (1), 1-13, 2017
432017
Imaging breast cancer using hyperpolarized carbon-13 MRI
FA Gallagher, R Woitek, MA McLean, AB Gill, RM Garcia, E Provenzano, ...
Proceedings of the National Academy of Sciences 117 (4), 2092-2098, 2020
392020
The effect of sleep deprivation and exercise on reaction threshold in peanut-allergic adults: a randomised controlled study
S Dua, M Ruiz-Garcia, S Bond, SR Durham, I Kimber, C Mills, G Roberts, ...
Journal of Allergy and Clinical Immunology, 2019
32*2019
Optimal multistage designs for randomised clinical trials with continuous outcomes
J Wason, AP Mander, SG Thompson
Statistics in Medicine, 2011
322011
Admissible two‐stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis
AP Mander, J Wason, MJ Sweeting, SG Thompson
Pharmaceutical Statistics 11 (2), 91-96, 2012
312012
Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design
M Dimairo, E Coates, P Pallmann, S Todd, SA Julious, T Jaki, J Wason, ...
BMC medicine 16 (1), 1-20, 2018
302018
The system can't perform the operation now. Try again later.
Articles 1–20